Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
J Drugs Dermatol ; 19(12): 1215-1218, 2020 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-33346518

RESUMEN

BACKGROUND: Topical platelet-rich plasma (PRP) must demonstrate stability to insure biologic activity in aesthetic medicine. OBJECTIVE: The objective of this research was to evaluate the role of platelet homeostasis in a novel PRP topical cosmetic formulation to provide facial appearance improvement. METHODS: The stability of the topical PRP formulation was evaluated in vitro followed by clinical in vivo testing. The in vitro evaluation examined platelet stability and morphology over a 90-day period within the preservative cosmetic base utilizing ELISA and light microscopy (LM)/scanning electron microscopy (SEM). The in vivo clinical study enrolled 20 subjects in a 120-day double blind split face study to evaluate the effect of 5–7x concentrated PRP compared to 2–3x concentrated PRP on facial photoaging. Cosmetic effect was evaluated by the subject and the dermatologist investigator on a 5-point ordinal scale at baseline, week 8, and week 16. RESULTS: 90-day stability for the topical PRP formulation was verified via ELISA and LM/SEM. ELISA showed the PRP was more inactive than control conditions via analyte concentration curves (PDGF-AB, EGF, and P-Selectin). LM/SEM demonstrated the PRP had less aggregation/activation over time within the cosmetic base and that refrigeration is superior to room-temperature storage thus delaying full platelet degranulation. The in vivo clinical study demonstrated parity between 20ml and 60ml PRP in terms of clinical efficacy. CONCLUSION: Platelets remain viable for up to 90 days in a refrigerated cosmetic vehicle with demonstrated topical clinical PRP facial benefits. PRP kits of 20ml and 60ml volumes for topical PRP are equally efficacious. J Drugs Dermatol. 2020;19(12): doi:10.36849/JDD.2020.5495.


Asunto(s)
Productos Biológicos/administración & dosificación , Plaquetas/fisiología , Transfusión de Sangre Autóloga/métodos , Plasma Rico en Plaquetas/citología , Envejecimiento de la Piel/efectos de los fármacos , Administración Cutánea , Productos Biológicos/química , Plaquetas/química , Degranulación de la Célula/fisiología , Supervivencia Celular/fisiología , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Estabilidad de Medicamentos , Almacenaje de Medicamentos , Femenino , Humanos , Masculino , Plasma Rico en Plaquetas/química , Conservadores Farmacéuticos/química , Piel/efectos de los fármacos , Piel/inmunología , Envejecimiento de la Piel/inmunología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA